Home »
Academic Articles & Research Papers
Showing 6 of 6 academic articles
Li Rong, Haiyu Li, Zhaodong Li, Jing Ouyang et al. • Frontiers in Medicine
(2020)
Background and Objective: Chemotherapy and radiotherapy are effective treatment options for cervical cancer (CC), but their efficacy is limited by short survival rate of about 5 years particularly for advance stage CC. Bioinformatics analys...
DOAJ
Open Access (DOAJ)
DOI: 10.3389/fmed.2020.608441
Jing Yang, Pengfei Li, Pengfei Li, Pengfei Li et al. • Frontiers in Immunology
(2022)
ObjectiveExtranodal natural killer/T cell lymphoma (NKTCL) is an aggressive EBV-related lymphoma, originating from NK cells or T cells. Previous study demonstrated that CD56 negative NKTCL should be recognized as a distinct subtype. In this...
DOAJ
Open Access (DOAJ)
DOI: 10.3389/fimmu.2022.829366
Wei Liu, Yan Xu, Yi Wang, Lugui Qiu et al. • Journal for ImmunoTherapy of Cancer
(2024)
Background Over 50% of patients with relapsed or refractory large B-cell lymphoma (r/r LBCL) receiving CD19-targeted chimeric antigen receptor (CAR19) T-cell therapy fail to achieve durable remission. Early identification of relapse or prog...
DOAJ
Open Access (DOAJ)
DOI: 10.1136/jitc-2023-008450
Chih‐Li Chen, Yu‐Shuen Tsai, Yen‐Hua Huang, Yuh‐Jin Liang et al. • Hepatology Communications
(2018)
Lymphoid enhancer factor 1 (LEF1) activity is associated with progression of several types of cancers. The role of LEF1 in progression of hepatocellular carcinoma (HCC) remains poorly known. We investigated LEF1 expression in HCC and its in...
DOAJ
Open Access (DOAJ)
DOI: 10.1002/hep4.1229
Xindong Wei, Anfeng Si, Shuai Zhao, Yi Fu et al. • Cellular & Molecular Biology Letters
(2025)
Abstract Background Circular (circ)RNAs have emerged as crucial contributors to cancer progression. Nonetheless, the expression regulation, biological functions, and underlying mechanisms of circRNAs in mediating hepatocellular carcinoma (H...
DOAJ
Open Access (DOAJ)
DOI: 10.1186/s11658-025-00690-1
Caroline W. Grant, Jerry Li, Swan Lin, Dana Nickens et al. • Clinical and Translational Science
(2025)
ABSTRACT Patient outcomes in advanced renal cell carcinoma (RCC) remain poor, with five‐year survival rates ranging from ~10% to 30%. Early projections of therapeutic outcomes could optimize precision medicine and accelerate drug developmen...
DOAJ
Open Access (DOAJ)
DOI: 10.1111/cts.70348